TOP TEN perturbations for 1272_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1272_at
Selected probe(set): 205321_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1272_at (205321_at) across 6672 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-4.844138
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

S. pneumoniae study 3 / S. pneumoniae study 4

Relative Expression (log2-ratio):3.7696352
Number of Samples:3 / 3
Experimental S. pneumoniae study 3
Detroit 562 pharyngeal epithelial cells, infected with Streptococcus pneumoniae isogenic nonencapsulated derivative G54delta-cps. Bacteria were allowed to adhere to the epithelial cells for 2 hours.
Control S. pneumoniae study 4
Detroit 562 pharyngeal epithelial cells, infected with Streptococcus pneumoniae G54WT. Bacteria were allowed to adhere to the epithelial cells for 2 hours.

kidney transplantation study 15 (4 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-3.6245346
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (4 week)
CD14+ monocyte samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

kidney transplantation study 13 (pre) / normal T-cell (CD8+) sample

Relative Expression (log2-ratio):-3.4025888
Number of Samples:4 / 5
Experimental kidney transplantation study 13 (pre)
CD8+ T-cell samples derived from kidney transplant patients pre-transplantation. Samples were collected immediately before transplantation and administration of immunosuppressive therapy.
Control normal T-cell (CD8+) sample
CD8+ T-cell samples derived from healthy control subjects.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):3.3507633
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

expO ovary cancer study 1 (mixed epithelial tumor; primary) / expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)

Relative Expression (log2-ratio):3.2349176
Number of Samples:3 / 3
Experimental expO ovary cancer study 1 (mixed epithelial tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with mixed epithelial tumor.
Control expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.949932
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.887766
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):2.7925682
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-2.7553883
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

Organism: Homo sapiens
Gene: 1272_at
Selected probe(set): 224935_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1272_at (224935_at) across 6672 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.9223976
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):2.3787699
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

cadmium study 1 (brief) / untreated NPrEC cell sample

Relative Expression (log2-ratio):-2.2353315
Number of Samples:2 / 2
Experimental cadmium study 1 (brief)
After 72h of starvation, NPrEC cells were briefly exposed to 2.5 uM CdCl2. ATC code:---
Control untreated NPrEC cell sample
After 72h of starvation, NPrEC cells were briefly exposed to complete medium without CdCl2.

expO ovary cancer study 1 (mixed epithelial tumor; primary) / expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)

Relative Expression (log2-ratio):2.2144089
Number of Samples:3 / 3
Experimental expO ovary cancer study 1 (mixed epithelial tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with mixed epithelial tumor.
Control expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.

myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.1581821
Number of Samples:5 / 3
Experimental myotonic dystrophy study 4 (skeletal muscle; DM1)
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):2.093958
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.0785398
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM2)
Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.0370636
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM-like)
Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.007372
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM2)
Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-1.9526825
Number of Samples:9 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM-like)
Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.